Key Points
- Insider sale: EVP Verneuil Vanina De sold 2,385 shares on Nov. 5 at an average price of $5.16 for $12,306.60, reducing her stake to 78,210 shares (about a 2.96% decrease) valued at roughly $403,564.
- Weak quarterly results: Vir reported EPS of ($1.17), missing the ($0.70) estimate by $0.47, with revenue of $0.24M versus a $1.98M consensus and extremely negative margins and return on equity.
- Analyst backdrop: Despite the miss, analysts are generally positive—MarketBeat shows a "Moderate Buy" consensus with an average price target of $17.30 (nine Buy, one Hold, one Sell)—while the stock trades near $5 (52‑week range $4.16–$14.45).
Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) EVP Verneuil Vanina De sold 2,385 shares of the stock in a transaction on Wednesday, November 5th. The shares were sold at an average price of $5.16, for a total value of $12,306.60. Following the sale, the executive vice president owned 78,210 shares in the company, valued at approximately $403,563.60. This represents a 2.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Verneuil Vanina De also recently made the following trade(s):
- On Monday, November 3rd, Verneuil Vanina De sold 1,365 shares of Vir Biotechnology stock. The stock was sold at an average price of $5.86, for a total transaction of $7,998.90.
Vir Biotechnology Stock Up 0.2%
NASDAQ VIR opened at $5.13 on Friday. Vir Biotechnology, Inc. has a 52 week low of $4.16 and a 52 week high of $14.45. The firm has a market capitalization of $712.66 million, a P/E ratio of -1.42 and a beta of 1.27. The company has a 50-day moving average price of $5.54 and a 200-day moving average price of $5.30.
Vir Biotechnology (NASDAQ:VIR - Get Free Report) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($1.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.70) by ($0.47). Vir Biotechnology had a negative net margin of 2,963.54% and a negative return on equity of 50.76%. The company had revenue of $0.24 million for the quarter, compared to the consensus estimate of $1.98 million. During the same quarter last year, the firm posted ($1.56) earnings per share. The company's revenue was up .8% compared to the same quarter last year. As a group, equities research analysts anticipate that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.
Wall Street Analyst Weigh In
A number of equities analysts have commented on the stock. Raymond James Financial initiated coverage on shares of Vir Biotechnology in a research note on Friday, July 11th. They issued an "outperform" rating on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $15.00 price target on shares of Vir Biotechnology in a report on Monday, September 15th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Vir Biotechnology in a research note on Wednesday. Bank of America upgraded shares of Vir Biotechnology from a "neutral" rating to a "buy" rating and increased their price target for the stock from $12.00 to $14.00 in a report on Wednesday, August 27th. Finally, Evercore ISI initiated coverage on shares of Vir Biotechnology in a report on Wednesday, September 3rd. They issued an "outperform" rating and a $12.00 price target on the stock. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $17.30.
View Our Latest Stock Report on VIR
Hedge Funds Weigh In On Vir Biotechnology
A number of large investors have recently bought and sold shares of VIR. Raymond James Financial Inc. acquired a new stake in Vir Biotechnology in the second quarter valued at approximately $35,000. GAMMA Investing LLC lifted its position in shares of Vir Biotechnology by 524.3% during the 1st quarter. GAMMA Investing LLC now owns 7,111 shares of the company's stock valued at $46,000 after buying an additional 5,972 shares in the last quarter. Federated Hermes Inc. grew its stake in Vir Biotechnology by 153.8% in the 3rd quarter. Federated Hermes Inc. now owns 8,085 shares of the company's stock valued at $46,000 after acquiring an additional 4,899 shares during the period. Apollon Wealth Management LLC purchased a new stake in Vir Biotechnology in the 2nd quarter worth $50,000. Finally, Daiwa Securities Group Inc. raised its position in Vir Biotechnology by 2,200.6% during the second quarter. Daiwa Securities Group Inc. now owns 12,308 shares of the company's stock worth $62,000 after acquiring an additional 11,773 shares during the period. Institutional investors and hedge funds own 65.32% of the company's stock.
About Vir Biotechnology
(
Get Free Report)
Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
